Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
A new weapon in the global fight against malaria
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Subscribe To Our Newsletter & Stay Updated